Redefining the value in partnerships ahead of DCAT Week

As the industry emerges from a prolonged funding slowdown, the roundtable highlights cautious optimism. Rather than a broad-based recovery, participants describe a selective, research-driven uptick focused on clinic-ready assets and higher-complexity modalities. Discussions have shifted from speculative experimentation to practical considerations, including manufacturability, timeline efficiency and the ability to scale reliably. This suggests growth that is deliberate, technology selective and weighted toward assets with clearer commercial pathways.

LATEST VIDEO

Latest news

2nd April 2026

Resyca Announces the Appointment of Deborah Jones as New CEO

1st April 2026

Saharsh Davuluri to take over as CEO & MD of Neuland and lead the next phase of CDMO expansion

1st April 2026

Adragos Pharma Finalize the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site at Maisons-Alfort, France, from Sanofi

1st April 2026

Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports

31st March 2026

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

31st March 2026

Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland

31st March 2026

Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development

31st March 2026

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31st March 2026

Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption

31st March 2026

Lonza Nominates Stephen Fry as Independent Board Member

30th March 2026

ImmuneOncia Therapeutics and Lonza Collaborate to Manufacture Danburstotug, a PD-L1 Antibody Targeting Immuno-Oncology

This week’s featured articles

A woman’s view from the HAS Group

Breaking Barriers: Women Scientists Rising to Leadership in Pharma

Strategic Growth in Biologics Manufacturing: Insights from Lonza's Acquisition of the Vacaville Site

Grifols’ supply chain strategy offers lessons beyond saline

Axplora: Mastering complexity

Partnered with top industry events and organisations